Compare PLRX & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLRX | RGR |
|---|---|---|
| Founded | 2015 | 1949 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ordnance And Accessories |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 601.9M |
| IPO Year | 2020 | 1994 |
| Metric | PLRX | RGR |
|---|---|---|
| Price | $1.11 | $37.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.67 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 408.2K | 105.5K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.07% |
| EPS Growth | ★ 29.97 | N/A |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $546,057,000.00 |
| Revenue This Year | N/A | $2.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $84.61 |
| Revenue Growth | N/A | ★ 1.94 |
| 52 Week Low | $1.02 | $28.33 |
| 52 Week High | $1.95 | $48.21 |
| Indicator | PLRX | RGR |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 43.86 |
| Support Level | $1.12 | $36.76 |
| Resistance Level | $1.26 | $39.04 |
| Average True Range (ATR) | 0.04 | 0.82 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 27.69 | 10.13 |
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States, and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.